TRex Bio sets terms for Nasdaq IPO of up to $128.7 million, with Lilly eyeing stake

6 October 2026

TRex Bio, the US clinical-stage immunology company built on regulatory T cell (Treg) biology, has set terms for a Nasdaq initial public offering of 8,333,334 shares priced at $14 to $16 each, under the proposed ticker TRXB.

At the $15 midpoint, TRex expects net proceeds of about $111.3 million, rising to $128.7 million if underwriters fully exercise an option to buy a further 1,250,000 shares, according to an amended S-1 filed with the SEC Monday.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Biotechnology